Remegen Co., Ltd.
Clinical trials sponsored by Remegen Co., Ltd., explained in plain language.
-
Promising NMOSD drug trial halted early – what happened?
Disease control TerminatedThis study tested an experimental drug called RC18 in 178 people with neuromyelitis optica spectrum disorders (NMOSD), a rare autoimmune disease that attacks the nerves. The goal was to see if RC18 could prevent relapses and slow disability. The trial was terminated early, so res…
Phase: PHASE3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
MS drug trial halted early: RC18 shows promise but needs more study
Disease control TerminatedThis early-stage trial tested an experimental drug called RC18 in 8 people with relapsing-remitting multiple sclerosis (MS). The goal was to see if it is safe and can reduce the number of MS attacks. The study was stopped early, so results are limited. RC18 works by targeting the…
Phase: PHASE2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC